Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04473261
  4. Details
NCT04473261 Clinical Trial

Efficacy of Iodine Complex Against COVID-19 Patients

Covid19 Clinical Trial

— I-COVID-PK  

Official title:
Efficacy of Iodine Complex in Mild to Moderate COVID-19 Patients

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04473261
Other study ID # SZMC/IRB/Internal/216/2020
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 14, 2020
Est. completion date October 15, 2021

Study information
Verified date July 2021
Source Sheikh Zayed Federal Postgraduate Medical Institute
Contact Sohaib Ashraf, MBBS
Phone +923334474523
Email sohaib-ashraf@outlook.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to measure the effect of Iodine complex in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.

Description:

The proposed study is a placebo-controlled, add-on, randomized trial using parallel group designs. This is a close-label and adaptive, multi-centered design with 1:1:1:1 allocation ratio and superiority framework.

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date October 15, 2021
Est. primary completion date August 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Positive PCR with mild to moderate disease Exclusion Criteria: - Allergic to iodine - Any co-morbidity other than hypertension and dietetics

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Iodine Complex
Iodine Complex capsule (200mg) will be given three times a day
• Iodine Complex
Iodine Complex syrup form (40ml) will be given three times a day
• Placebo
Empty capsule will be given as placebo
• Idoine Complex
Iodine Complex spray form 2 puffs will be given three times a day

Locations
Country Name City State
Pakistan Shaikh Zayed Hospital Lahore

Sponsors (1)
Lead Sponsor Collaborator
Sohaib Ashraf

Country where clinical trial is conducted

Pakistan, 

Outcome
Type Measure Description Time frame Safety issue
Primary qRT-PCR Time taken for viral load clearance 14 days
Primary HRCT chest Time taken for radiological improvement 14 days
Secondary Severity of Symptoms Time taken for symptomatic response in patients 14 days
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3